Isofol Medical (Q4 Review): Translational year ahead - Redeye

Redeye provides a research update following the Q4 report recently published by Isofol. The report came in largely in line with our estimates, with only a slightly lower OPEX than anticipated. With a bolstered cash position through the oversubscribed rights issue and a successfully completed second dose level in the phase Ib/II study, we continue to have a positive outlook on the company.

Länk till analysen i sin helhet: https://www.redeye.se/research/1152233/isofol-medical-q4-review-translational-year-ahead?utm_source=finwire&utm_medium=RSS